Durata Therapeutics, Inc. Initiates Enrollment In A Phase 3b Study Of Dalvance™ In A 1500 Mg Single Dose
Published: Apr 24, 2014
CHICAGO, April 24, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced that it has initiated enrollment of a Phase 3b clinical trial to evaluate the efficacy and safety of its investigational product, Dalvance™ (dalbavancin) for injection, in a single 1500 milligram dose infused over 30 minutes in adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive bacteria.
Help employers find you! Check out all the jobs and post your resume.